MDMB-CHMINACA (also known as MDMB(N)-CHM) is an indazole-based synthetic cannabinoid that acts as a potent agonist of the CB1 receptor and has been sold online as a designer drug. It was invented by Pfizer in 2008 and is one of the most potent cannabinoid agonists known, with a binding affinity of 0.0944 nM at CB1, and an EC50 of 0.330 nM. It is closely related to MDMB-FUBINACA, which caused at least 1000 hospitalizations and 40 deaths in Russia as a consequence of intoxication.
Buy MDMB-CHMINACA Online
MDMB-CHMICA (also incorrectly known as MMB-CHMINACA) is an indole-based synthetic cannabinoid that is a potent agonist of the CB1 receptor and has been sold online as a designer drug. While MDMB-CHMICA was initially sold under the name �MMB-CHMINACA�, the compound corresponding to this code name (i.e. the isopropyl instead of t-butyl analog of MDMB-CHMINACA) has been identified on the designer drug market in 2015 as AMB-CHMINACA.